[HTML][HTML] Immune checkpoint inhibitors in the treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
Immune Checkpoint Inhibitors in the Treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
Immune Checkpoint Inhibitors in the Treatment of HCC.
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Frontiers in …, 2020 - europepmc.org
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
Immune Checkpoint Inhibitors in the Treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - FRONTIERS IN …, 2021 - iris.unica.it
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
Immune Checkpoint Inhibitors in the Treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Frontiers in …, 2021 - cir.nii.ac.jp
抄録< jats: p> Hepatocellular carcinoma (HCC) is the typical inflammation-induced
neoplasia. It often prospers where a chronic liver disease persists, thus leading a strong …
neoplasia. It often prospers where a chronic liver disease persists, thus leading a strong …
[HTML][HTML] Immune Checkpoint Inhibitors in the Treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
[PDF][PDF] Immune Checkpoint Inhibitors in the Treatment of HCC. Front
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Oncol, 2021 - lirias.kuleuven.be
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
Immune Checkpoint Inhibitors in the Treatment of HCC
C Donisi, M Puzzoni, P Ziranu, E Lai… - Immunotherapy in …, 2021 - books.google.com
Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M,
Migliari M, Pretta A, Liscia N, Astara G and Scartozzi M (2021) Immune Checkpoint Inhibitors …
Migliari M, Pretta A, Liscia N, Astara G and Scartozzi M (2021) Immune Checkpoint Inhibitors …
[PDF][PDF] Immune Checkpoint Inhibitors in the Treatment of HCC. Front
C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Oncol, 2021 - iris.unica.it
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …